Cansino Biologics Inc. (688185.SH): The freeze-dried b-type influenza Haemophilus influenzae conjugate vaccine has initiated Phase I clinical trials and completed enrollment of the first subject.

On November 15, Glonghui reported that cansino biologics inc. (688185.SH) announced the official launch of phase I clinical trials for its lyophilized Haemophilus influenzae type b conjugate vaccine (hereinafter referred to as the "Hib vaccine"), and completed the enrollment of the first subject. The Hib vaccine developed by the company is made from purified Hib capsular polysaccharide covalently combined with tetanus toxin protein, and is formulated as a lyophilized dosage form, which is expected to induce humoral immunity against Hib after vaccination, providing protection to the vaccinated individuals.

Gelonghui FinanceNov 15 03:33 ET

CanSino Biologics Inc.'s (HKG:6185) Shares Bounce 37% But Its Business Still Trails The Industry

Simply Wall StNov 11 17:21 ET

Most pharmaceutical stocks rose, with Tongyuan Kangyi Medicine (02410) up 18.46%. Institutions pointed out that the policy trend of medical insurance funds supporting innovative drugs will not change.

Jingwu Cai Xun | Most pharmaceutical stocks rose, with Tongyuan Kang Medicine (02410) up 18.46%, Keji Pharmaceutical (02171) up 13.86%, Heyu (02256) up 11.79%, Cloud Peak Xin Yao (01952) up 10.31%, cansinobio (06185) up 7.48%. Zhong Yin International stated that benefiting from overseas interest rate cuts and domestic macroeconomic improvement, the pharmaceutical industry, as a high elasticity industry, is expected to outperform the market. The bank believes that the performance of the macroeconomy is closely related to the revenue and expenditure of medical insurance funds and medical health consumer spending. As policy focus shifts to stimulating the economy, the bank believes that medical industry

Golden Guardian Financial NewsNov 8 01:59 ET

Results: CanSino Biologics Inc. Confounded Analyst Expectations With A Surprise Profit

Simply Wall StOct 31 19:13 ET

Third Quarter Report 2024

SZSIOct 29 12:00 ET · Announcements

Cansino Biologics Inc. (688185.SH) released its performance for the first three quarters, with a net loss of 0.222 billion yuan.

Cansino Biologics Inc. (688185.SH) released the third quarter report for 2024, with a revenue of 5.6...

Zhitong FinanceOct 29 10:48 ET